Amsterdam, The Netherlands - 18 July 2018

Following earlier information provided regarding the delay on the publication of the Annual Report 2017 mainly due to technical issues which have now been identified, Esperite regrets to inform that the issuance of the Annual Report will be further delayed despite the effort spent over the last months.

Esperite N.V will communicate as soon as a release date is foreseen.

About ESPERITE
ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.
To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar: +31 575 548 998 - ir@esperite.com or visit the websites at www.esperite.com,  www.genoma.com and www.cryo-save.com.

***

This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).

Delay AR July 2018


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Esperite N.V. via Globenewswire